Italian in vitro diagnostics firm Diasorin said on Sunday that the US Food and Drug Administration has issued 510(k) clearance and CLIA-waived the firm's first assay for use on the Liaison Nes platform.

Following decades of cumulative efforts, a number of infectious disease tests and technologies broke new ground in 2025, hinting at rapid advances in the development of new systems and assays. But the past year also saw its fair share of upheaval, possibly suggesting more may be in store in 2026.

"In the past, when we talked about sexually active populations, we mainly referred to people aged 20 to 49, who accounted for the majority of HIV infections. But now, infection rates among people aged 50 and above are increasing."

Becton Dickinson said Monday that its partner Certest Biotec has received In Vitro Diagnostic Medical Device Regulation certifications in Europe for two infectious disease assays.

Pfizer and Dynamiker Biotechnology signed a strategic cooperation agreement on December 1, 2025.

Roche announced Tuesday that its PCR-based test for vaginitis has received CE marking. The test is now available in countries accepting the designation.

Diagnostics firm IdentifySensors Biologics has recently demonstrated proof of concept for the use of its electrochemical sensor-based diagnostic platform Check4 for cancer testing and is now moving closer to commercialization of the platform and related tests.

New research suggests that individuals who consistently carry Staphylococcus aureusin their noses have other nasal microbial community features that are distinct from those found in individuals without persistent S. aureus colonization.

In honour of World AIDS Day 2025, AIDS Healthcare Foundation (AHF) UK will host two community events to emphasize that the work to end HIV/AIDS is not over.

Sysmex and Qiagen's Japanese subsidiary said Tuesday that they have expanded their longstanding partnership to include the distribution of clinical diagnostic products for infectious diseases and cancer in Japan.